Gene therapy for tuberous sclerosis
US-2024343768-A1 · Oct 17, 2024 · US
Heat shock protein GP96 vaccination and methods of using same
US8968720B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8968720-B2 |
| Application number | US-93356709-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 19, 2009 |
| Priority date | Mar 20, 2008 |
| Publication date | Mar 3, 2015 |
| Grant date | Mar 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a heat shock protein (hsp) gp96 polypeptide. The invention also provides a method of stimulating an immune response to a tumor by administering a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a gp96 polypeptide.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of reducing the growth rate of an established cancerous tumor in a subject, the method comprising the step of administering to the subject a vaccine comprising cancer cells secreting gp96, wherein the cancer cells: (i) have been transfected with a vector comprising a nucleic acid encoding a secreted form of gp96 which lacks a KDEL endoplasmic reticulum retention sequence, (ii) are of the same type as the established tumor, and (iii) are a source of t…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8968720B2 cover?
- The invention provides a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a heat shock protein (hsp) gp96 polypeptide. The invention also provides a method of stimulating an immune response to a tumor by administering a tumor cell genetically modified to express a nucleic acid encoding a secreted form of a gp96 polypeptide.
- Who is the assignee on this patent?
- Podack Eckhard R, Rosenblatt Joseph R, Univ Miami
- What technology area does this patent fall under?
- Primary CPC classification A61K38/1709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).